49 related articles for article (PubMed ID: 23684358)
1. Randomized trial of simplified LV5FU2 versus FOLFOX7 followed by FOLFIRI (MIROX) in patients with initially resectable metastatic colorectal cancer: a GERCOR study.
Hebbar M; Chibaudel B; André T; Louvet C; Smith D; Mineur L; Bennamoun M; Mabro M; Brusquant D; Bonnetain F; Pruvot FR; de Gramont A
J Chemother; 2013 Apr; 25(2):104-11. PubMed ID: 23684358
[TBL] [Abstract][Full Text] [Related]
2. FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial.
Hebbar M; Chibaudel B; André T; Mineur L; Smith D; Louvet C; Dutel JL; Ychou M; Legoux JL; Mabro M; Faroux R; Auby D; Brusquant D; Khalil A; Truant S; Hadengue A; Dalban C; Gayet B; Paye F; Pruvot FR; Bonnetain F; Landi B; Flesch M; Carola E; Martin P; Vaillant E; de Gramont A;
Ann Oncol; 2015 Feb; 26(2):340-7. PubMed ID: 25403578
[TBL] [Abstract][Full Text] [Related]
3. Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study.
Taïeb J; Artru P; Paye F; Louvet C; Perez N; André T; Gayet B; Hebbar M; Goebel FM; Tournigand C; Parc R; de Gramont A
J Clin Oncol; 2005 Jan; 23(3):502-9. PubMed ID: 15659495
[TBL] [Abstract][Full Text] [Related]
4. Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial.
Hamidou Z; Chibaudel B; Hebbar M; Hug de Larauze M; André T; Louvet C; Brusquant D; Garcia-Larnicol ML; de Gramont A; Bonnetain F
PLoS One; 2016; 11(6):e0157067. PubMed ID: 27310205
[TBL] [Abstract][Full Text] [Related]
5. [Reflexion on a good strategy of use of oxaliplatine with 5-fluorouracil and its derivatives in patients with advanced colorectal cancer].
Tournigand C; de Gramont A
Bull Cancer; 2006 Feb; 93 Suppl 1():S11-5. PubMed ID: 16483941
[TBL] [Abstract][Full Text] [Related]
6. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
[TBL] [Abstract][Full Text] [Related]
7. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
Tournigand C; Cervantes A; Figer A; Lledo G; Flesch M; Buyse M; Mineur L; Carola E; Etienne PL; Rivera F; Chirivella I; Perez-Staub N; Louvet C; André T; Tabah-Fisch I; de Gramont A
J Clin Oncol; 2006 Jan; 24(3):394-400. PubMed ID: 16421419
[TBL] [Abstract][Full Text] [Related]
8. FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study.
Figer A; Perez-Staub N; Carola E; Tournigand C; Lledo G; Flesch M; Barcelo R; Cervantes A; André T; Colin P; Louvet C; de Gramont A
Cancer; 2007 Dec; 110(12):2666-71. PubMed ID: 17963264
[TBL] [Abstract][Full Text] [Related]
9. Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment).
Modest DP; Schulz C; von Weikersthal LF; Quietzsch D; von Einem JC; Schalhorn A; Vehling-Kaiser U; Laubender RP; Giessen C; Stintzing S; Heinemann V
Anticancer Drugs; 2014 Feb; 25(2):212-8. PubMed ID: 24201305
[TBL] [Abstract][Full Text] [Related]
10. High-dose irinotecan plus LV5FU2 or simplified LV5FU (HD-FOLFIRI) for patients with untreated metastatic colorectal cancer: a new way to allow resection of liver metastases?
Ducreux M; Raoul JL; Marti P; Merrouche Y; Tigaud JM; Rebischung C; Boige V
Oncology; 2008; 74(1-2):17-24. PubMed ID: 18536526
[TBL] [Abstract][Full Text] [Related]
11. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.
Chibaudel B; Maindrault-Goebel F; Lledo G; Mineur L; André T; Bennamoun M; Mabro M; Artru P; Carola E; Flesch M; Dupuis O; Colin P; Larsen AK; Afchain P; Tournigand C; Louvet C; de Gramont A
J Clin Oncol; 2009 Dec; 27(34):5727-33. PubMed ID: 19786657
[TBL] [Abstract][Full Text] [Related]
12. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
Bendell JC; Tournigand C; Swieboda-Sadlej A; Barone C; Wainberg ZA; Kim JG; Pericay C; Pastorelli D; Tarazi J; Rosbrook B; Bloom J; Ricart AD; Kim S; Sobrero AF
Clin Colorectal Cancer; 2013 Dec; 12(4):239-47. PubMed ID: 24188685
[TBL] [Abstract][Full Text] [Related]
13. A Randomized Phase II Study of Leucovorin/5-Fluorouracil with or without Oxaliplatin (LV5FU2 vs. FOLFOX) for Curatively-Resected, Node-Positive Esophageal Squamous Cell Carcinoma.
Lim SH; Shim YM; Park SH; Kim HK; Choi YS; Ahn MJ; Park K; Zo JI; Sun JM
Cancer Res Treat; 2017 Jul; 49(3):816-823. PubMed ID: 27857024
[TBL] [Abstract][Full Text] [Related]
14. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy.
Hecht JR; Pillai M; Gollard R; Heim W; Swan F; Patel R; Dreiling L; Mo M; Malik I
Clin Colorectal Cancer; 2010 Apr; 9(2):95-101. PubMed ID: 20378503
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis.
Masi G; Vasile E; Loupakis F; Cupini S; Fornaro L; Baldi G; Salvatore L; Cremolini C; Stasi I; Brunetti I; Fabbri MA; Puglisi M; Trenta P; Granetto C; Chiara S; Fioretto L; Allegrini G; Crinò L; Andreuccetti M; Falcone A
J Natl Cancer Inst; 2011 Jan; 103(1):21-30. PubMed ID: 21123833
[TBL] [Abstract][Full Text] [Related]
16. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure.
Boige V; Malka D; Elias D; Castaing M; De Baere T; Goere D; Dromain C; Pocard M; Ducreux M
Ann Surg Oncol; 2008 Jan; 15(1):219-26. PubMed ID: 17896145
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trial.
Ychou M; Rivoire M; Thezenas S; Quenet F; Delpero JR; Rebischung C; Letoublon C; Guimbaud R; Francois E; Ducreux M; Desseigne F; Fabre JM; Assenat E
Ann Surg Oncol; 2013 Dec; 20(13):4289-97. PubMed ID: 23955585
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
19. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Van Cutsem E; Tabernero J; Lakomy R; Prenen H; Prausová J; Macarulla T; Ruff P; van Hazel GA; Moiseyenko V; Ferry D; McKendrick J; Polikoff J; Tellier A; Castan R; Allegra C
J Clin Oncol; 2012 Oct; 30(28):3499-506. PubMed ID: 22949147
[TBL] [Abstract][Full Text] [Related]
20. Clinical and economic evaluation of first-line therapy with FOLFIRI or modified FOLFOX6 for metastatic colorectal cancer.
Ajima H; Ogata H; Fujita K; Miwa K; Sunakawa Y; Mizuno K; Ishida H; Yamashita K; Nakayama H; Kawara K; Takahashi H; Sasaki Y
Jpn J Clin Oncol; 2010 Jul; 40(7):634-8. PubMed ID: 20587616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]